The Roche collaboration transforms the risk/reward profile, investors should watch for the HSR/antitrust clearance timeline (expected Q3) triggering the $700M payment. Key catalysts ahead: DAYBreak CLL-201 pivotal data, Phase 1b combo data at upcoming medical meetings, and initiation of Phase 2 in CSU/MS. The $0.81 EPS miss vs -$0.72 consensus is backward-looking noise given the platform validation; focus on enrollment updates for the registrational CLL trial.
Drugs in focus
NRIX drug pipeline →bexobrutideg
▲ Bullish Named in this press release- Impact
- Phase
- Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- Time to market
- 3-5 years (Phase 3 trials starting summer 2026; potential accelerated approval pathway via pivotal Phase 2 data could compress timeline)
- Next catalyst
- None dated
What to watchThe Roche deal ($700M upfront, up to $2.3B total) already provided the major derisking catalyst, the stock surged ~70% on the June 8 announcement. Watch for HSR antitrust clearance (expected Q3 2026), Phase 3 trial initiation in CLL this summer, and any early data from planned Phase 2 starts in autoimmune (CSU) and neurology (MS). Analyst consensus is Strong Buy with mean PT of $31.44, but the stock already reflects significant partnership premium, new upside will require compelling Phase 2/3 data execution, not just partnership validation.
- ● GS-6791 4/10 Phase 1 Named in filing
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned) Named in filing
- ● zelebrudomide 3/10 Phase 1 Named in filing
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting Named in filing
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $23.06entry
- T+1 · 4mo ago −1.52%α −0.75% · $22.71
- T+5 · 4mo ago +0.04%α +0.60% · $23.07
- T+20 · 3mo ago +10.71%α +8.29% · $25.53
- T+60 · 6w ago −0.78%α −3.41% · $22.88
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss) and EPS of -$0.81 vs consensus -$0.72 (-12.5% miss) following a year-ago quarter that included $30M in license fees. The revenue miss is largely explained by the absence of the prior-year Sanofi license payments, but the operational spend ramp (R&D up 12% YoY) drove net loss to -$89.5M vs -$43.5M. The dominant positive event is the global Roche collaboration for bexobrutideg, which brings a $700M near-term cash infusion (expected closing in Q3) and total potential milestones of $2.3B, dramatically extending the cash runway to ~$1.14B pro-forma and validating the BTK degrader platform across oncology, immunology, and neurology.
Key Financial Metrics
Key Facts
- Revenue $9.0M miss vs consensus $15.3M (-41%); prior year $44.1M included $30M in Sanofi license fees
- EPS -$0.81 miss vs consensus -$0.72 (-12.5%); prior year -$0.52
- Net loss -$89.5M vs -$43.5M; R&D spend $87.7M (+12% YoY)
- Cash/investments $443.5M as of May 31, 2026; pro-forma ~$1.14B after Roche upfront
- Roche collaboration: $700M upfront (expected Q3 FY26), up to $2.3B total milestones; 40/60 cost split; 50/50 US profit share
- Bexobrutideg pivotal CLL trial (DAYBreak CLL-201) ongoing; Phase 3 vs pirtobrutinib expected mid-2026
- Phase 1b ORR 92.9% (Cohort 5) and 84.2% (Cohort 15) in CLL; median PFS 22.1 mo
- Expansion planned into CSU Phase 2 and MS Phase 2
- Sanofi milestone earned $2M; Gilead IRAK-4 degrader in Phase 1; Pfizer DAC programs ongoing
Financial Impact
$700M near-term cash injection via Roche upfront; total deal value up to $2.3B inclusive of milestones; 40/60 cost sharing reduces future R&D cash burden
Risk Factors
- Roche collaboration subject to HSR and antitrust clearances, delay or failure to close
- Pivotal CLL trial DAYBreak CLL-201 may not support Accelerated Approval
- Bexobrutideg faces competitive pressure from pirtobrutinib and other BTK inhibitors/degraders
- Net loss expanding: -$176.7M year-to-date vs -$99.8M prior year; operational burn ~$100M/quarter
- Cash/equivalents $67.7M low vs near-term $700M Roche payment, any delay strains liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325185 |
Track record
33 reports on NRIX
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers